NEW YORK–(BUSINESS WIRE)–Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board. The board is composed of four distinguished physicians and scientists who will contribute insights from their vast experience as Kallyope advances its proprietary drug discovery platform, clinical trials, and pipeline of therapeutic programs.
“Over the past seven years, we have built a highly efficient drug discovery organization that has now advanced several novel molecules into clinical trials,” said Jay Galeota, president and CEO, Kallyope. “As we expand into our next phase, we will be drawing on the wisdom and expertise of external leaders in clinical development. All four of these leaders have initiated and guided development programs with far-reaching impact on global medicine. Their objective insight, immense experience, and broad perspective will further enable us to realize our ultimate objective to advance human health.”
The Kallyope Clinical Development Advisory Board
Jeffrey Chodakewitz, M.D., is a specialist in internal medicine and infectious diseases with expertise in both early- and late-stage drug development across small and large molecules, as well as broad R&D and organizational experience in large and small companies. He retired in 2019 as past chief medical officer and executive vice president, Clinical Medicine and External Innovation at Vertex Pharmaceuticals, and he currently serves on several boards of directors. Previously, Dr. Chodakewitz spent 23 years at Merck Research Laboratories, holding senior positions in therapeutic areas and in cross-portfolio roles.
Thomas Koestler, Ph.D., has more than 35 years of experience in the pharmaceutical industry working with companies across the full spectrum of development stages, and has guided more than 80 programs to FDA submission and approval, including more than 30 new molecular entities and biologics. Dr. Koestler served as executive vice president of Schering Corporation and president of Schering-Plough Research Institute, and previously was senior vice president and Head of Global Regulatory Affairs for Pharmacia Corporation. He has held executive positions at Novartis Pharmaceuticals, Sandoz Pharmaceuticals, Ortho McNeil, Bristol-Myers Squibb, Westwood Pharmaceuticals and Vatera Healthcare. Dr. Koestler also served as chairman of the Scientific Advisory Board of Bausch & Lomb and has been a member of the boards of directors of Novo Nordisk, Momenta Pharmaceuticals, Melinta Therapeutics, and Edgemont Pharmaceuticals.
Scott Korn, M.D., has more than 30 years of global regulatory and drug development experience. He has provided strategic regulatory leadership at all phases of drug development for small molecules and biologics, with a successful track record of numerous submissions and approvals in multiple therapeutic areas. Dr. Korn began his biopharma industry career at Merck Research Laboratories, where he continues to work today. He has held roles in clinical research, drug safety and regulatory affairs. He served as vice president of Global Regulatory Affairs for general medicine and currently holds that position for oncology and in vitro diagnostics. Dr. Korn has extensive experience interacting with the United States Food and Drug Administration, the European Medicines Agency, and other leading regulatory agencies.
Elizabeth Stoner, M.D., is executive partner at MPM Capital and senior clinical advisor of AlloVir, and most recently served as that company’s interim chief medical officer. She has decades of global industry experience and has held several leadership roles at other MPM portfolio companies, including interim CEO of Semma Therapeutics; founder, chief medical officer and chief development officer of Rhythm Pharmaceuticals, and chief development officer of Vascular Pharmaceuticals. Prior to joining MPM, Dr. Stoner was senior vice president of Global Clinical Development Operations at Merck Research Laboratories, where she was responsible for clinical development activities in more than 40 countries.
Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company’s cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. For more information, visit www.kallyope.com.